GlassScriptPhysician profile
Forest R Conley
NPI 1982603452
$6,314.15
in general payments reported to CMS, 2019-2025
36 companies · $75.53 in 2025
The $75.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $1,359 · 2021: $1,790 · 2022: $1,227 · 2023: $572 · 2024: $393 · 2025: $75.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $955.45 | 2019-2024 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $726.10 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $648.82 | 2021-2024 | Ubrelvy, Vraylar |
| Pfizer INC. | $559.70 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.57 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $293.81 | 2019-2023 | |
| Glaxosmithkline, LLC. | $281.27 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $281.02 | 2019-2022 | |
| Novo Nordisk INC | $265.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $255.97 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.90 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $188.49 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $114.71 | 2019-2021 | |
| Amgen INC. | $112.93 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $111.47 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $111.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.93 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $102.56 | 2022-2023 | Rexulti |
| Abbott Laboratories | $82.00 | 2022-2024 | Freestyle Libre 3 |
| Radius Health, INC. | $77.22 | 2019-2024 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $70.09 | 2020-2021 | |
| Amarin Pharma, INC. | $63.61 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $51.94 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Grifols USA, LLC | $48.48 | 2019 | |
| Eisai INC. | $42.21 | 2020-2021 | |
| Genentech USA, INC. | $40.74 | 2019-2022 | |
| Mylan Specialty L.P. | $39.36 | 2022-2023 | Yupelri |
| Nevro Corp. | $39.06 | 2023 | Senza |
| Exact Sciences Corporation | $38.49 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $22.78 | 2022 | |
| Viatris Specialty LLC | $16.83 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $16.51 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.25 | 2022 | |
| Neurocrine Biosciences, INC. | $15.03 | 2025 | |
| Globus Medical, INC. | $14.71 | 2025 | Senza |
| Lundbeck LLC | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forest Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.